ClinicalTrials.gg
CompletedNCT03006887Updated May 20, 2021Results posted

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

A Phase 1 interventional study of lenvatinib and pembrolizumab in Solid Tumors, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-05-20.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 4 under way, 1 of them phase 3. lenvatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 14
6 · median 29
Started
2017
the only one that year
Phase 1
2 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
2 of 14
Eisai Co., Ltd.

Among the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma [excluding uveal melanoma]).

03

Conditions studied

  • Solid Tumors

Keywords

  • solid tumors
  • non-small cell lung cancer
  • predominantly clear cell renal cell carcinoma
  • endometrial carcinoma
  • urothelial carcinoma
  • squamous cell carcinoma of the head and neck
  • non-uveal melanoma
  • E7080
  • lenvatinib
  • pembrolizumab
  • Japan
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically confirmed selected solid tumor types that have progressed after treatment with standard therapies or for which there are no other appropriate therapies available.

The selected tumor types are: non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)

  • At least 1 measurable target lesion according to modified (RECIST) 1.1
  • Participants must have an (ECOG)-Performance Status (PS) of 0 to 1.
  • Adequate liver function as evidenced by ≤1.5× and alkaline phosphatase (ALP), (ALT), and aspartate aminotransferase (AST) ≤3×ULN (in the case of liver ≤5×ULN). In case ALP is >3×ULN (in the absence of liver metastases) or >5×ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.
  • Males or females age ≥20 years at the time of
  • of 12 weeks or more
  • Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  • Prior anticancer treatment within 28 days (or 5 times the half-life time, whichever is shorter) or any agent within 28 days prior to the first dose of study drugs. All toxicities related to prior treatments must be resolved to Grade ≤1 (except alopecia).
  • Prior treatment with lenvatinib or any , anti-PD-L1, or anti-PD-L2 agent, excluding cancer types such as melanoma and non-small cell lung cancer where prior treatment with one anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is allowed
  • Participants must have recovered adequately from any complications from major surgery prior to starting therapy.
  • congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months
  • Prolongation of (Fridericia formula) interval to >480 milliseconds (ms)
  • Active infection (any infection requiring systemic treatment)
  • Participant is known to be positive for (HIV), , or
  • Known intolerance to either of the study drugs (or any of the )
  • History of organ allograft
  • Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial
  • Has a history of (non-infectious) pneumonitis that required or current pneumonitis, or has a history of interstitial lung disease
  • Females who are breastfeeding or pregnant at Screening or Baseline.
  • Females of .
  • Participants must be on a stable dose of the same oral hormonal product for at least 4 weeks before dosing with study drug and for the duration of the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    lenvatinib 20 mg plus pembrolizumab 200 mg

    Participants with selected tumors will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once daily in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.

    Drug: lenvatinib · Drug: pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A TEAE was defined as an adverse event (AE) that emerged during the time from the first dose of study drug to 30 days following the last dose of study drug, having been absent at pretreatment (Baseline) or reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. A Serious AE is any untoward medical occurrence that at any dose: resulted in death; was life threatening (that is, the participant was at immediate risk of death from the AE as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death) required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

    Time frame: From the first dose until 30 days after the last dose (approximately 2 years 7 months)

  2. Number of Participants With Dose-limiting Toxicities

    A DLT is defined as any of the following: any of the hematological or nonhematological toxicities specified in the protocol that are considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1; failed to administer greater than or equal to 75 percent (%) of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1; participants who discontinued due to treatment-related toxicity in Cycle 1; greater than a 2-week delay in starting pembrolizumab in Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria.

    Time frame: Cycle 1 (Cycle length=21 days)

Secondary outcomes

  1. Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

    ORR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) for target and non-target lesions. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in the short axis to less than 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The tumor assessment was done using number of lesions based on modified RECIST 1.1 for assessing tumor burden up to 10 target lesions with up to 5 target lesions per organ.

    Time frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years 7 months

  2. Duration of Response (DOR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

    DOR was defined as time from the first documented of CR or PR to the date of first documentation of disease progression (PD) (based on modified RECIST 1.1) or death (whichever occurs first). CR was defined as the disappearance of all target lesions and non-target lesions. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD for target lesion, was defined as a minimum 20% increase and a minimum 5 mm absolute increase in sum of diameters compared to nadir, or PD for non-target lesion(s) or unequivocal new lesion(s). Nadir was defined as lowest measure sum of diameters of target lesions at any time point from baseline onward. The tumor assessment was done using number of lesions based on modified RECIST 1.1 for assessing tumor burden up to 10 target lesions with up to 5 target lesions per organ. DOR = Date of PD/death (whichever occurs first) - Date of first CR or PR + 1.

    Time frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years 7 months.

  3. Cmax: Maximum Plasma Concentration of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours

  4. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours

  5. T1/2: Terminal Half-life of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours

  6. AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours

  7. AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours

  8. Vz/F: Apparent Volume of Distribution at Terminal Phase of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours

  9. CL/F: Apparent Total Clearance Following Oral Dosing of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours

  10. MRT: Mean Residence Time of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours

  11. Css,Max: Maximum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 15: 0-24 hours

  12. Css,Min: Minimum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 15: 0-24 hours

  13. Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 15: 0-24 hours

  14. AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 15: 0-24 hours

  15. Clss/F: Apparent Total Clearance Following Oral Administration at Steady State of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 15: 0-24 hours

  16. Css,Av: Average Steady State Plasma Concentration of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 15: 0-24 hours

  17. Rac (Cmax): Accumulation Index of Cmax for Lenvatinib in Combination With Pembrolizumab

    Rac (Cmax) was calculated as the ratio of drug concentrations observed during a dosing interval at steady state divided by drug concentrations seen during the dosing interval after a single (first) dose. Rac (Cmax) = Css,max on Cycle 1 Day 15 / Cmax on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1: 0-24 hours and Cycle 1 Day 15: 0-24 hours

  18. Rac (AUC): Accumulation Index of AUC for Lenvatinib in Combination With Pembrolizumab

    Rac (AUC) was calculated as the ratio of drug concentrations observed during a dosing interval at steady state divided by drug concentrations seen during the dosing interval after a single (first) dose. Rac (AUC) = AUC(0-t) on Cycle 1 Day 15 / AUC(0-t) on Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1: 0-24 hours and Cycle 1 Day 15: 0-24 hours

  19. Lambda z: Terminal Phase Elimination Rate Constant of Lenvatinib in Combination With Pembrolizumab

    Time frame: Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours

  20. PTF: Peak-trough Fluctuation Ratio of Lenvatinib in Combination With Pembrolizumab

    The peak trough fluctuation within complete dosing interval at steady state, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

    Time frame: Cycle 1 Day 15: 0-24 hours

  21. Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status for Pembrolizumab

    Time frame: Day 1 of Cycles 1, 2, 4, 6, and 8 and every 4 cycles thereafter; within 30 days after discontinuation or until the initiation of other anticancer treatment, whichever is earlier (Cycle length=21 days); up to 31 months

07

Results

Posted May 20, 2021

Participant flow

Participants took part in the study at 1 investigative site in Japan from 12 Jan 2017 to 15 Apr 2020.

Participant flow — Overall Study
MilestoneLenvatinib 20 mg Plus Pembrolizumab 200 mg
Started6
Completed5
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

A TEAE was defined as an adverse event (AE) that emerged during the time from the first dose of study drug to 30 days following the last dose of study drug, having been absent at pretreatment (Baseline) or reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. A Serious AE is any untoward medical occurrence that at any dose: resulted in death; was life threatening (that is, the participant was at immediate risk of death from the AE as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death) required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

Time frame:
From the first dose until 30 days after the last dose (approximately 2 years 7 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsLenvatinib 20 mg Plus Pembrolizumab 200 mg
TEAEs6
SAEs4
PrimaryNumber of Participants With Dose-limiting Toxicities

A DLT is defined as any of the following: any of the hematological or nonhematological toxicities specified in the protocol that are considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1; failed to administer greater than or equal to 75 percent (%) of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1; participants who discontinued due to treatment-related toxicity in Cycle 1; greater than a 2-week delay in starting pembrolizumab in Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria.

Time frame:
Cycle 1 (Cycle length=21 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities
ParticipantsLenvatinib 20 mg Plus Pembrolizumab 200 mg
Number of Participants With Dose-limiting Toxicities0
SecondaryObjective Response Rate (ORR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

ORR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) for target and non-target lesions. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in the short axis to less than 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The tumor assessment was done using number of lesions based on modified RECIST 1.1 for assessing tumor burden up to 10 target lesions with up to 5 target lesions per organ.

Time frame:
From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years 7 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
percentage of participantsLenvatinib 20 mg Plus Pembrolizumab 200 mg
Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.133.3
SecondaryDuration of Response (DOR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

DOR was defined as time from the first documented of CR or PR to the date of first documentation of disease progression (PD) (based on modified RECIST 1.1) or death (whichever occurs first). CR was defined as the disappearance of all target lesions and non-target lesions. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD for target lesion, was defined as a minimum 20% increase and a minimum 5 mm absolute increase in sum of diameters compared to nadir, or PD for non-target lesion(s) or unequivocal new lesion(s). Nadir was defined as lowest measure sum of diameters of target lesions at any time point from baseline onward. The tumor assessment was done using number of lesions based on modified RECIST 1.1 for assessing tumor burden up to 10 target lesions with up to 5 target lesions per organ. DOR = Date of PD/death (whichever occurs first) - Date of first CR or PR + 1.

Time frame:
From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years 7 months.
Reported as:
Median · months
Duration of Response (DOR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
monthsLenvatinib 20 mg Plus Pembrolizumab 200 mg
Duration of Response (DOR) Based on Modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1NA (16.79 to NA)
SecondaryCmax: Maximum Plasma Concentration of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Plasma Concentration of Lenvatinib in Combination With Pembrolizumab
nanogram per milliliter (ng/mL)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
Cmax: Maximum Plasma Concentration of Lenvatinib in Combination With Pembrolizumab325 ± 233
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of Lenvatinib in Combination With Pembrolizumab
hoursLenvatinib 20 mg Plus Pembrolizumab 200 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of Lenvatinib in Combination With Pembrolizumab3.85 (1.78 to 7.02)
SecondaryT1/2: Terminal Half-life of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours
Reported as:
Median · hours
T1/2: Terminal Half-life of Lenvatinib in Combination With Pembrolizumab
hoursLenvatinib 20 mg Plus Pembrolizumab 200 mg
Cycle 1 Day 15.62 (5.52 to 5.71)
Cycle 1 Day 157.26 (6.95 to 7.57)
SecondaryAUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of Lenvatinib in Combination With Pembrolizumab
nanogram*hour per milliliter (ng*h/mL)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
Cycle 1 Day 13040 ± 1780
Cycle 1 Day 154280 ± 2600
SecondaryAUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours
Reported as:
Geometric mean · ng*h/mL
AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of Lenvatinib in Combination With Pembrolizumab
ng*h/mLLenvatinib 20 mg Plus Pembrolizumab 200 mg
AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of Lenvatinib in Combination With Pembrolizumab3880 ± 2090
SecondaryVz/F: Apparent Volume of Distribution at Terminal Phase of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · liter (L)
Vz/F: Apparent Volume of Distribution at Terminal Phase of Lenvatinib in Combination With Pembrolizumab
liter (L)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
Cycle 1 Day 141.8 ± 23.5
Cycle 1 Day 1526.1 ± 0.636
SecondaryCL/F: Apparent Total Clearance Following Oral Dosing of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours
Reported as:
Geometric mean · liter per hour (L/hr)
CL/F: Apparent Total Clearance Following Oral Dosing of Lenvatinib in Combination With Pembrolizumab
liter per hour (L/hr)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
CL/F: Apparent Total Clearance Following Oral Dosing of Lenvatinib in Combination With Pembrolizumab5.15 ± 2.78
SecondaryMRT: Mean Residence Time of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · hours
MRT: Mean Residence Time of Lenvatinib in Combination With Pembrolizumab
hoursLenvatinib 20 mg Plus Pembrolizumab 200 mg
Cycle 1 Day 19.06 ± 0.983
Cycle 1 Day 1511.8 ± 0.141
SecondaryCss,Max: Maximum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · ng/mL
Css,Max: Maximum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab
ng/mLLenvatinib 20 mg Plus Pembrolizumab 200 mg
Css,Max: Maximum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab355 ± 319
SecondaryCss,Min: Minimum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · ng/mL
Css,Min: Minimum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab
ng/mLLenvatinib 20 mg Plus Pembrolizumab 200 mg
Css,Min: Minimum Observed Plasma Concentration at Steady State of Lenvatinib in Combination With Pembrolizumab60.1 ± 24.6
SecondaryTss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 15: 0-24 hours
Reported as:
Median · hours
Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State of Lenvatinib in Combination With Pembrolizumab
hoursLenvatinib 20 mg Plus Pembrolizumab 200 mg
Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State of Lenvatinib in Combination With Pembrolizumab7.14 (2.07 to 7.83)
SecondaryAUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · ng*h/mL
AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval of Lenvatinib in Combination With Pembrolizumab
ng*h/mLLenvatinib 20 mg Plus Pembrolizumab 200 mg
AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval of Lenvatinib in Combination With Pembrolizumab6780 ± 1820
SecondaryClss/F: Apparent Total Clearance Following Oral Administration at Steady State of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · L/h
Clss/F: Apparent Total Clearance Following Oral Administration at Steady State of Lenvatinib in Combination With Pembrolizumab
L/hLenvatinib 20 mg Plus Pembrolizumab 200 mg
Clss/F: Apparent Total Clearance Following Oral Administration at Steady State of Lenvatinib in Combination With Pembrolizumab2.95 ± 0.932
SecondaryCss,Av: Average Steady State Plasma Concentration of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · ng/mL
Css,Av: Average Steady State Plasma Concentration of Lenvatinib in Combination With Pembrolizumab
ng/mLLenvatinib 20 mg Plus Pembrolizumab 200 mg
Css,Av: Average Steady State Plasma Concentration of Lenvatinib in Combination With Pembrolizumab283 ± 75.8
SecondaryRac (Cmax): Accumulation Index of Cmax for Lenvatinib in Combination With Pembrolizumab

Rac (Cmax) was calculated as the ratio of drug concentrations observed during a dosing interval at steady state divided by drug concentrations seen during the dosing interval after a single (first) dose. Rac (Cmax) = Css,max on Cycle 1 Day 15 / Cmax on Cycle 1 Day 1

Time frame:
Cycle 1 Day 1: 0-24 hours and Cycle 1 Day 15: 0-24 hours
Reported as:
Mean · ratio
Rac (Cmax): Accumulation Index of Cmax for Lenvatinib in Combination With Pembrolizumab
ratioLenvatinib 20 mg Plus Pembrolizumab 200 mg
Rac (Cmax): Accumulation Index of Cmax for Lenvatinib in Combination With Pembrolizumab1.14 ± 0.376
SecondaryRac (AUC): Accumulation Index of AUC for Lenvatinib in Combination With Pembrolizumab

Rac (AUC) was calculated as the ratio of drug concentrations observed during a dosing interval at steady state divided by drug concentrations seen during the dosing interval after a single (first) dose. Rac (AUC) = AUC(0-t) on Cycle 1 Day 15 / AUC(0-t) on Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1: 0-24 hours and Cycle 1 Day 15: 0-24 hours
Reported as:
Mean · ratio
Rac (AUC): Accumulation Index of AUC for Lenvatinib in Combination With Pembrolizumab
ratioLenvatinib 20 mg Plus Pembrolizumab 200 mg
Rac (AUC): Accumulation Index of AUC for Lenvatinib in Combination With Pembrolizumab1.46 ± 0.450
SecondaryLambda z: Terminal Phase Elimination Rate Constant of Lenvatinib in Combination With Pembrolizumab
Time frame:
Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · 1/hour
Lambda z: Terminal Phase Elimination Rate Constant of Lenvatinib in Combination With Pembrolizumab
1/hourLenvatinib 20 mg Plus Pembrolizumab 200 mg
Cycle 1 Day 10.123 ± 0.00354
Cycle 1 Day 150.0956 ± 0.00573
SecondaryPTF: Peak-trough Fluctuation Ratio of Lenvatinib in Combination With Pembrolizumab

The peak trough fluctuation within complete dosing interval at steady state, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

Time frame:
Cycle 1 Day 15: 0-24 hours
Reported as:
Geometric mean · Percentage fluctuation
PTF: Peak-trough Fluctuation Ratio of Lenvatinib in Combination With Pembrolizumab
Percentage fluctuationLenvatinib 20 mg Plus Pembrolizumab 200 mg
PTF: Peak-trough Fluctuation Ratio of Lenvatinib in Combination With Pembrolizumab194 ± 48.8
SecondaryNumber of Participants Positive for Serum Anti-drug Antibodies (ADA) Status for Pembrolizumab
Time frame:
Day 1 of Cycles 1, 2, 4, 6, and 8 and every 4 cycles thereafter; within 30 days after discontinuation or until the initiation of other anticancer treatment, whichever is earlier (Cycle length=21 days); up to 31 months
Reported as:
Count of participants · Participants
Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status for Pembrolizumab
ParticipantsLenvatinib 20 mg Plus Pembrolizumab 200 mg
Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status for Pembrolizumab0

Adverse events

Collected over Baseline up to 30 days after last dose of study drug (approximately 2 years 7 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 20 mg Plus Pembrolizumab 200 mg0/6 (0%)4/6 (66.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventLenvatinib 20 mg Plus Pembrolizumab 200 mg
SubileusGastrointestinal disorders1/6
Bile duct stenosisHepatobiliary disorders1/6
PneumonitisRespiratory, thoracic and mediastinal disorders1/6
Aspergillus infectionInfections and infestations1/6
Most frequent other events
Showing 10 of 63
Most frequent other events
EventLenvatinib 20 mg Plus Pembrolizumab 200 mg
Aspartate aminotransferase increasedInvestigations6/6
HypertensionVascular disorders6/6
HypothyroidismEndocrine disorders5/6
FatigueGeneral disorders5/6
Alanine aminotransferase increasedInvestigations5/6
NauseaGastrointestinal disorders4/6
Decreased appetiteMetabolism and nutrition disorders4/6
ProteinuriaRenal and urinary disorders4/6
Gamma-glutamyltransferase increasedInvestigations3/6
Lipase increasedInvestigations3/6

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
Mean55.0 ± 13.39
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
Female3
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib 20 mg Plus Pembrolizumab 200 mg
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Eisai Trial Site 1
    Chuo-ku, Tokyo, Japan
09

References and documents

Publications

  • Kitano S, Fujiwara Y, Shimizu T, Iwasa S, Yonemori K, Kondo S, Shimomura A, Koyama T, Ebata T, Ikezawa H, Hayata N, Minoshima Y, Miura T, Kubota T, Yamamoto N. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2022 Dec;90(6):523-529. doi: 10.1007/s00280-022-04480-w. Epub 2022 Oct 26. PubMed 36289094 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2020, 39 months.

Results were first posted in May 2021, 1 year 1 month after primary completion.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 39 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2016
First posted
Dec 30, 2016
StartActual
Jan 12, 2017
Primary completionActual
Apr 15, 2020
CompletionActual
Apr 15, 2020
Results first posted
May 20, 2021
Last update
May 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03006887
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Dec 30, 2016
Start date
Jan 12, 2017
Primary completion
Apr 15, 2020
Completion
Apr 15, 2020
Results posted
May 20, 2021
Last update
May 20, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Pembrolizumab

Start the discussion